Copyright
©The Author(s) 2022.
World J Methodol. Sep 20, 2022; 12(5): 438-447
Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.438
Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.438
Refs | Study duration | Type of study | Region/place | Main findings |
Myhre et al[23], 2020 | March 18, 2020 to May 4, 2020 | Prospective, observational study | Norway | GDF-15 has a better prognostic significance than recognized inflammatory biomarkers like CRP, ferritin, procalcitonin, and IL-6 |
Notz et al[24], 2020 | March 14 to May 28, 2020 | A single-center retrospective study | Germany | There was no evident imbalance of pro-and anti-inflammatory pathways, with higher GDF-15 levels in patients with SARS-CoV-2 infection during ICU stay, implying elevated tissue resilience |
Luis García de Guadiana Romualdo et al[25], 2021 | March 14 to April 12, 2020 | Case-series | Spain | The GDF level was significantly high in nonsurvivors compared to survivors of SARS-CoV-2 infection, and it may be useful to predict prognosis |
Teng et al[26], 2021 | January 22, 2020, to May 13, 2020 | Retrospective study | China | GDF-15 could be used as a biomarker to predict the severity of SARS-CoV-2 infection. GDF-15 level increased consistently with increased severity of SARS-CoV-2 infection, and GDF-15 expression returned to normal level similarly in a convalescent group compared to the healthy control participants. Hence, it implies that the GDF-15 precisely monitors the progression of SARS-CoV-2 infection |
Kanberg et al[27], 2021 | February 21 to November 5, 2020 | Prospective study | Sweden | Patients with severe and moderate SARS-CoV-2 infection exhibited significantly increased GDF-15 levels compared with participants with mild infection and controls throughout the acute phase. Even after 6 mo of infection, GDF-15 concentrations persisted considerably higher in the severe and moderate infections compared to patients with mild infection and controls |
Ebihara et al[28], 2022 | August 2020 to December 2020 | Prospective multicenter observational study | Japan | GDF-15 may be beneficial to predict delayed recovery or mortality of SARS-CoV-2-infected patients during ICU treatment |
Alserawan et al[29], 2021 | Not mentioned | Prospective study | Spain | GDF-15 may play a role in categorizing SARS-CoV-2-infected patients based on severityGDF-15 is an excellent biomarker to detect impaired respiratory function compared to CRP and D-dimer |
- Citation: Parchwani D, Dholariya S, Katoch C, Singh R. Growth differentiation factor 15 as an emerging novel biomarker in SARS-CoV-2 infection. World J Methodol 2022; 12(5): 438-447
- URL: https://www.wjgnet.com/2222-0682/full/v12/i5/438.htm
- DOI: https://dx.doi.org/10.5662/wjm.v12.i5.438